Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Pharmacol Ther. 2018 Jun 30;192:1–19. doi: 10.1016/j.pharmthera.2018.06.015

Figure 3. Soluble epoxide hydrolase (sEH) inhibitor development to treat renal and cardiovascular diseases.

Figure 3

DCU: one of the initial amide, urea, and carbamate classes found to be a potent and stable transition state sEH inhibitor. AUDA: the first sEH inhibitor to be administered orally. Merck-1: a piperidine-derived urea sEH inhibitor. Merck-2: a novel aminohetroaryls that inhibit sEH. Boehringer Ingelheim: a pyrazole amide sEHO inhibitor. Arête Therapeutics AR9281 : the first sEH inhibitor to be tested in humans for hypertension and diabetes. GSK GSK2256294A: second sEH inhibitor to be tested in humans for the indication of chronic obstructive pulmonary disease (COPD).